GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » Institutional Ownership

SLXN (Silexion Therapeutics) Institutional Ownership : 8.44% (As of Dec. 14, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Silexion Therapeutics's institutional ownership is 8.44%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Silexion Therapeutics's Insider Ownership is 51.32%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Silexion Therapeutics's Float Percentage Of Total Shares Outstanding is 72.70%.


Silexion Therapeutics Institutional Ownership Historical Data

The historical data trend for Silexion Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics Institutional Ownership Chart

Silexion Therapeutics Historical Data

The historical data trend for Silexion Therapeutics can be seen below:

2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 0.05 0.05 0.04 0.04

Silexion Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Silexion Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
2 Ha mayan Street, Modi in-Maccabim-Reut, ISR, 7177871
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.